Protalix BioTherapeutics PLX
NYSE PLX
$2.54 -0.03 (-1.12%)
As of: Oct 23, 2026 · 3:59 PM EDT

Protalix BioTherapeutics (PLX) Gains from Sales and Divestitures (2010 - 2021)

Updated

Protalix BioTherapeutics (PLX) posted Gains from Sales and Divestitures of $3,000 for FY2024, compared with -$9,000 in FY2023.

Analysis

Protalix BioTherapeutics (PLX) Gains from Sales and Divestitures (2010 - 2021) Analysis & Trends

Since FY2009, Protalix BioTherapeutics has reported Gains from Sales and Divestitures for 9 years.

  • Annual Gains from Sales and Divestitures shows a three-year compound annual growth rate of -61.1% (FY2021 to FY2024).
  • The FY2024 figure stands as the highest annual Gains from Sales and Divestitures since FY2021.
  • Business Quant data shows PLX's Gains from Sales and Divestitures at -$9,000 in FY2023 and $51,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Protalix BioTherapeutics 204.37 Mn 52.98 Mn 12.13 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 51,000.00
Dec 31, 2011 -6,000.00
Sep 30, 2011 -2,000.00
Sep 30, 2010 -3,000.00
API Access

Protalix BioTherapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PLX&period=max&api_key=YOUR_API_KEY